| Literature DB >> 24155906 |
Piotr Janusz1, Tomasz Kotwicki, Miroslaw Andrusiewicz, Malgorzata Kotwicka.
Abstract
INTRODUCTION: XbaI single nucleotide polymorphism (SNP) (A/G rs934099) in estrogen receptor 1 gene (ESR1) was described to be associated with curve severity in Japanese idiopathic scoliosis (IS) patients and in Chinese patients with both curve severity and predisposition to IS. PvuII SNP (C/T rs2234693) of ESR1 was described to be associated with the occurrence of IS in the Chinese population; however, two replication studies did not confirm the findings. The ESR1 SNPs have never been studied in Caucasian IS patients.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24155906 PMCID: PMC3796567 DOI: 10.1371/journal.pone.0076806
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Phenotype description for case-control study.
| Cases | Controls | |
| N = 287 | N = 182 | |
| females/males | females | females |
| age range (years) | 10–59 | 16–64 |
| age mean ±SD (years) | 17.9±8.6 | 28.3±10 |
| menarche | yes or no | yes (more than 2 years after) |
| family history of scoliosis | positive or negative | negative |
| back deformity | idiopathic scoliosis (rib hump) | no deformity |
| curve pattern | all | NA |
| Cobb angle at final visit | 10°–114° | NA |
| Cobb angle at final visit mean ±SD | 39.4°±19.0° | NA |
| angle of trunk rotation in degrees (Bunell scoliometer) | NA | <4° |
NA – non applicable.
Phenotype description for case only study in skeletally matured patients with non-progressive (NP-IS), slowly progressive (SP-IS) and rapidly progressive (RP-IS) idiopathic scoliosis.
| cases N = 253 | |||
| phenotype subgroups | NP-IS | SP-IS | RP-IS |
| N = 93 | N = 104 | N = 56 | |
| age range (years) | 16–52 | 16–59 | 12–54 |
| Risser | 4 or 5 | 4 or 5 | all |
| skeletal maturity | yes | yes | no |
| back deformity | idiopathic scoliosis (rib hump) | idiopathic scoliosis (rib hump) | idiopathic scoliosis (rib hump) |
| curve pattern | all | all | all |
| Cobb angle at final visit (range) | 10°–30° | 30°–65° | 35°–114° |
| Cobb angle at final visit (mean ±SD) | 23.3°±5.6° | 40.3°±9.2° | 69.5°±19.2° |
| progression rate in degrees per month (range) | NA | 0.04°–0.95° | 1.0°–3.2° |
NA – non applicable.
Primers' description.
| Sequence 5′–>3′ | annealing temp | amplicon length | |
| ESR1_rs9340799_XbaI_F |
| 71°C | 1300 bp |
| ESR1_rs9340799_XbaI_R |
| ||
| ESR1_rs2234693_PuvII_F |
| 60°C | 759 bp |
| ESR1_rs2234693_PuvII_R |
|
PCRs reactions thermal profiles.
| Step | ESR1 – first amplicon | ESR1 – second amplicon | ||
| duration | cycles no. | duration | cycles no. | |
| Initial denaturation | 95°C, 5 min | 1 | 95°C, 5 min | 1 |
| Denaturation | 95°C, 20 sec | 30 | 95°C, 30 sec | 40 |
| Annealing | 71°C, 15 sec | 30 | 60°C, 30 sec | 40 |
| Elongation | 72°C, 15 sec | 30 | 70°C, 1.20 sec | 40 |
| Final elongation | 72°C, 3 min | 1 | 70°C, 5 min | 1 |
RFLP SNPs fragment description.
| recognition site | Allele | digestion product length | |
| ESR1_rs9340799_XbaI | T | T | 910bp +390bp |
| TCTGGA | 1300bp | ||
| ESR1_rs2234693_PuvII | CAG | CAG | 271bp +488 bp |
| CAGCCG | 759 bp |
digestion site.
Allele and genotype frequency for IS patients and healthy controls.
| SNP | IS patients N = 287 | HWE | Healthy controls N = 182 | HWE | p value | p value | p value | Odds ratio (95% CI) | ||
| XbaI | Genotype | AA | 33.5% (96) | 33.5% (61) | ||||||
| AG | 49.1% (141) | 0.89 | 50.5% (92) | 0.56 | 0.7696 | 0.9880 | 0.3685 | 0.90 (0.54–1.48)** | ||
| GG | 17.4% (50) | 15.9% (29) | 0.99 (0.67–1.48)*** | |||||||
| Allele | A | 58.0% (333) | 58.8% (214) | |||||||
| G | 42.0% (241) | 41.2% (150) | 0.8671 | 0.97 (0.74–1.26) | ||||||
| PvuII | Genotype | TT | 26.8% (77) | 23.1% (42) | ||||||
| TC | 50.2% (144) | 0.93 | 51.1% (93) | 0.76 | 0.5572 | 0.4230 | 0.6046 | 1.17 (0.76–179)** | ||
| CC | 23.0% (66) | 25.8% (47) | 1.22 (0.79–1.88)*** | |||||||
| Allele | T | 51.9% (298) | 48.6% (177) | |||||||
| C | 48.1% (276) | 51.4% (187) | 0.3601 | 0.14 (0.87–1.48) | ||||||
Chi2 test.
Dominant model contrasts: for XbaI XX and Xx vs xx, for PvuII PP and Pp vs pp.
Recessive model contrasts: for XabI XX vs Xx and xx, for PvuII PP vs Pp and pp.
Haplotype frequency for IS patients and healthy controls.
| Haplotype | |||||
| AT | AC | GT | GC | p value | |
| Patients | 49.1% (282) | 8.9% (51) | 2.8% (16) | 39.2% (225) | |
| Controls | 44.8% (163) | 14.0% (51) | 3.8% (14) | 37.4% (136) | 0.0645 |
calculated with WinHAP [21].
Chi2 test.
Allele and genotype frequency for the patients with non-progressive (NP-IS), slowly progressive (SP-IS) and rapidly progressive (RP-IS) idiopathic scoliosis (N = 253).
| SNP | NP-IS | SP-IS | RP-IS | p value | p value | p value | ||||
| N = 93 | N = 104 | N = 56 | ||||||||
| % (n) | HWE | % (n) | HWE | % (n) | HWE | |||||
| XbaI | AA | 38.7% (36) | 28.9% (30) | 33.9% (19) | ||||||
| AG | 41.9% (39) | 0.21 | 56.7% (59) | 0.11 | 42.9% (24) | 0.32 | ||||
| GG | 19.4% (18) | 14.4% (15) | 23.2% (13) | 0.3629 | 0.5498 | 0.2194 | ||||
| PvuII | TT | 24.7% (23) | 26.9% (28) | 30.4% (17) | ||||||
| TC | 53.8% (50) | 0.46 | 52.9% (55) | 0.52 | 37.5% (21) | 0.06 | ||||
| CC | 21.5% (20) | 20.2% (21) | 32.1% (18) | 0.2041 | 0.7546 | 0.2830 | ||||
Chi2 test.
Dominant model contrasts: for XbaI XX and Xx vs xx, for PvuII PP and Pp vs pp.
Recessive model contrasts: for XabI XX vs Xx and xx, for PvuII PP vs Pp and pp.
Haplotype frequency for the patients with non-progressive (NP-IS), slowly progressive (SP-IS) and rapidly progressive (RP-IS) idiopathic scoliosis.
| Haplotype | |||||
| AT | AC | GT | GC | p value | |
| NP-IS | 48.9% (91) | 10.8% (20) | 2.7% (5) | 37.6% (70) | |
| SP-IS | 50.5% (105) | 6.7% (14) | 2.9% (6) | 39.9% (83) | 0.8482 |
| RP-IS | 45.5% (51) | 9.8% (11) | 3.6% (4) | 41.1% (46) | |
calculated with WinHAP [21].
Chi2 test.
Genotype according to Cobb angle, progression or surgical treatment (N = 253).
| XbaI (rs9340799) | p value | PvuII (rs2234693) | p value | |||||
| Genotype | AA | AG | GG | TT | TC | CC | ||
| Number of subjects | 85 | 122 | 46 | 68 | 126 | 59 | ||
| Mean Cobb angle (±SD) | 38.7±21.2 | 38.6±18.8 | 38.1±18.0 | 0.8475 | 40.9±19.7 | 36.4±19.2 | 40.4±19.5 | 0.1499 |
| Cobb ange<40° | 34.1% (55) | 49.1% (79) | 16.8% (27) | 24.8% (40) | 41.3% (88) | 20.5% (33) | ||
| Cobb ange≥40° | 32.6% (30) | 46.7% (43) | 20.7% (19) | 0.7434 | 30.4% (28) | 41.3% (38) | 28.3% (26) | 0.1170 |
| Documented progression >5° | 31.1% (41) | 48.5% (64) | 20.4% (27) | 27.3% (36) | 44.7% (59) | 28.0% (37) | ||
| Documented lack of progression | 36.4% (44) | 47.9% (58) | 15.7% (19) | 0.5178 | 19.0% (23) | 55.4% (67) | 25.6% (31) | 0.1800 |
| Patients undergoing surgery | 35.8% (24) | 44.8% (30) | 19.4% (13) | 29.9% (20) | 40.2% (27) | 29.9% (20) | ||
| Patients without surgery | 32.8% (61) | 49.5% (92) | 17.7% (33) | 0.8052 | 25.8% (48) | 53.2% (99) | 21.0% (39) | 0.1637 |
Kruskal-Wallis test,.
Chi2 test.
Genotype according to curve level and curve pattern (N = 253).
| XbaI (rs9340799) | p value | PvuII (rs2234693) | p value | |||||
| Genotype | AA | AG | GG | TT | TC | CC | ||
| Main thoracic curve | 33.0% (59) | 50.8% (91) | 16.2% (29) | 27.4% (49) | 50.3% (90) | 22.3% (40) | ||
| Main lumbar curve | 35.1% (26) | 41.9% (31) | 23.0% (17) | 0.3525 | 25.7% (19) | 48.6% (36) | 25.7% (19) | 0.8466 |
| Single curve | 37.5% (39) | 46.2% (48) | 16.3% (17) | 26.0% (27) | 51.9% (54) | 22.1% (23) | ||
| Double curve | 30.9% (46) | 49.7% (74) | 19.4% (29) | 0.5261 | 27.5% (41) | 48.3% (72) | 24.2% (36) | 0.8502 |
Chi2 test.
Haplotype according to Cobb angle, progression or surgical treatment.
| Haplotype | |||||
| AT | AC | GT | GC | p value | |
| Patients with Cobb <40° | 49.4% (159) | 9.3% (30) | 2.8% (9) | 38.5% (124) | |
| Patients with Cobb ≥40° | 47.8% (88) | 8.2% (15) | 3.2% (6) | 40.8% (75) | 0.9248 |
| Documented progression >5° | 46.2% (122) | 9.1% (24) | 4.2% (11) | 40.5% (107) | |
| Documented lack of progression | 51.6% (125) | 8.7% (21) | 1.7% (4) | 38.0% (92) | 0.2976 |
| Patients undergoing surgery | 47.8% (64) | 10.4% (14) | 2.2% (3) | 39.6% (53) | |
| Patients without surgery | 49.2% (183) | 8.3% (31) | 3.2% (12) | 39.3% (146) | 0.8344 |
calculated with WinHAP [21].
Chi2 test.
Tabel 13. Haplotype according to curve level and curve pattern.
| Haplotype | |||||
| AT | AC | GT | GC | p value | |
| Main thoracic curve | 50.6% (181) | 7.8% (28) | 2.0% (7) | 39.6% (142) | |
| Main lumbar curve | 44.6% (66) | 11.5% (17) | 5.4% (8) | 38.5% (57) | 0.0864 |
| Single curve | 50.9% (106) | 9.6% (20) | 1.0% (2) | 38.5% (80) | |
| Double curve | 47.3% (141) | 8.4% (25) | 4.4% (13) | 39.9% (119) | 0.1455 |
calculated with WinHAP [21].
Chi2 test.
Comparison of genotype frequency in 182 controls in this study versus controls from other studies concerning Caucasian populations.
| N | XbaI (rs9340799) | p value | PvuII (rs2234693) | p value | |||||
| AA | A/G | GG | TT | C/T | CC | ||||
| Hap Map CEU | 59 | 29 | 25 | 5 | 0.0711 | 28 | 58 | 17 | 0.1889 |
| Becherini et al. | 610 | 213 | 280 | 117 | 0.4664 | 177 | 299 | 134 | 0.2437 |
| Patel et al. | 662 | 273 | 307 | 82 | 0.1324 | 197 | 333 | 132 | 0.1003 |
| Molvarec et al. | 180 | 60 | 93 | 27 | 0.9637 | 45 | 94 | 41 | 0.7761 |
| Ignaszak-Szczepaniak et al. | 163 | 65 | 84 | 14 | 0.0958 | 42 | 78 | 43 | 0.7991 |
| Stavrou et al. | 145 | 54 | 56 | 35 | 0.0599 | 41 | 53 | 51 | 0.0296 |
| Roszkowska-Gancarz et al | 414 | 157 | 194 | 63 | 0.5852 | 118 | 199 | 97 | 0.3823 |
Chi2 test.